aidot

[View original text]

AI-based ‘Cerviray’ confirmed to be supplied to 100 obstetrics and gynecologists in Indonesia by the end of the year

On 12th of August, AIDOT (CEO Jae-hoon Jeong) announced that its artificial intelligence-based cervical cancer screening system, Cerviray has been officially registered with the 

Indonesian Procurement Service.

AIDOT completed official approval from Indonesia's MOH (Ministry of Health) in April this year, and successfully commercialized it in the local market. With the official registration with the Indonesian Procurement Service, it is expected to gain more strength in expanding the local market.

PT Pyridam Pharma, AIDOT's local indonesian partner said, "As a result of examining Indonesian cervical cancer screening methods, many HPV test methods and cell test methods do not fit the reality of Indonesia. For this reason, we have confirmed that the AI-based VIA method 'Cerviray' is the best cervical cancer screening method.” 

In particular, AIDOT visited Indonesia on the 8th and successfully completed Cerviray training and seminars at major tertiary large hospitals. Also, by the end of this year, it has 

decided to supply  Cerviray system to about 100 hospitals, mainly in Indonesia.

As Cerviray was registered as an official medical device with the Indonesian Procurement Service, it was possible to further expand supply through public procurement.

Garam Lim, Head of AIDOT Global Sales and Marketing Team, who supervised the local training in Indonesia expressed expectations and said, “This training allowed Pyridam Pharma to better understand Cerviray and solidify their partnership. Based on this, sales activities will be actively carried out in the Indonesian market."

Then she emphasized, "Through this local training, we will contribute to the eradication of cervical cancer among Indonesian women and the advancement of AIDOT into the global 

market."

12th.Aug.2022 / Medical Times / Reporter Hyun-ki Kim